What kind of expertise do you need?

News & Insights
World Pharma Pricing & Market Access Congress 2019
Precision will be attending the 2019 World Pharma Pricing & Market Access Congress on March 19th and 20th in Amsterdam!
In addition to visiting our sponsor booth, we encourage you to attend Precision thought leaders Basmah Khogeer and Nusayba Anjarwalla’s research presentation—full details follow:
Tumour-Agnostic Agents: Are They Fit for Reimbursement?
March 19, 2019
HTA Track
In May 2017, the United States Food and Drug Administration (FDA) approved pembrolizumab, an anti-PD1 immunotherapy, for unresectable or metastatic solid tumours identified as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This marked the first ever approval for a so-called tumour/site-agnostic indication for an oncology treatment. With several other oncology drugs in development for tumour/site-agnostic indications (e.g. larotrectinib and Debio 1347), the objective of this research was to explore the health technology assessment (HTA) challenges that may arise when assessing these drugs for reimbursement in Europe, should they obtain Marketing Authorization from the European Medicines Agency.
For more information on the Congress, please click here.
Contact us
Discover exactly what Precision can do for you. We look forward to learning about your needs, exploring how we can support you, and sharing our proven approaches. For information and inquiries, please contact:
Zac Stillerman
Zac Stillerman
President and General Manager
phone-icon +1 240.316.3451
Larry Blandford
Larry Blandford, PharmD
Executive Vice President and Managing Partner
phone-icon +1 212.686.2650
J. Bruce Leavitt
J. Bruce Leavitt, MBA
Executive Vice President and Managing Partner
phone-icon +1 203.487.5240
Ross Maclean
Ross Maclean, MD, PHD, MBA
Executive Vice President, General Manager
phone-icon +1 310.984.7708
Harry Grant Schiavi
Harry Grant Schiavi
Managing Partner
phone-icon +1 302.379.1702